Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
News|Articles|March 2, 2014
Capsule filler
Capsule filler
Advertisement
MG America offers the new FlexaLAB Capsule Filler, which can produce up to 3000 capsules/hr. Specifically designed for R&D labs, clinical trials, small batch outputs and special productions, Flexa-LAB can function at continuous or intermittent motion. Multiple dosing units can be utilized simultaneously, enabling the FlexaLAB to manufacture capsules with product combinations.
MG America, Fairfield, NJ
•
INTERPHEX Booth # 2253
Advertisement
Related to this article
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5